An estimated 4.8 million people in the United States are now eligible to receive the new COVID vaccination.
But the COID vaccine trial has been plagued by setbacks, and there are signs the vaccine may be nearing completion.
The first phase of the vaccine trial was canceled because of COVID, and the next two phases are still in the process of being approved by the Food and Drug Administration.
In a statement, the vaccine’s manufacturer, Sanofi Pasteur, said that after further analysis, it was determined that the trial would not proceed with an acceptable vaccine composition for the current strain of the COFF-19 vaccine.
The new strain, developed by Sanofi, has been described as being more potent and safe.
Sanofi Pasteud said it was able to meet the COV-19 vaccination challenge because of its new vaccine composition, and added that it was working on a vaccine to be available in 2018.
According to a statement by the National Institute of Allergy and Infectious Diseases, the current vaccine composition has not been demonstrated to be effective against the new strain of COFF, nor have the results of clinical trials conducted in humans demonstrated that it is safe for use in people with a history of COV.
“The safety of the current COVID vaccines was demonstrated in clinical trials in people, and safety of future COVID vaccinations will be determined by more rigorous and more extensive clinical trials that use an additional, safer vaccine, and will continue to monitor the safety of our vaccines,” the statement said.
However, it is not clear whether the current study, conducted by a small group of researchers at the National Institutes of Health (NIH), has reached the same conclusions.
“These preliminary results provide preliminary evidence that the current dose-response data does not provide sufficient data to determine whether the existing dose-reactivity data will provide a reliable indication of efficacy against COVID,” the NIH said in a statement.
Some scientists believe the current data is too small, and that the data should be analyzed further.
Sanofi has also stated that it will continue working with researchers in other countries, including China, where it operates its vaccine manufacturing facility.
It is unclear when the new vaccine formulation for the new generation of COX-2 vaccines will be available.
At this time, the COX vaccine trials are expected to run through the end of 2019.
Follow Ryan Saavedra on Twitter at @ryan_saavedra.
Read or Share this story: http://usat.ly/1Qpwf5H